Results 41 to 50 of about 20,990 (167)

CIP2A Promotes T-Cell Activation and Immune Response to Listeria monocytogenes Infection. [PDF]

PLoS ONE, 2016
The oncoprotein Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) is overexpressed in most malignancies and is an obvious candidate target protein for future cancer therapies. However, the physiological importance of CIP2A-mediated PP2A inhibition is
Christophe Côme, Anna Cvrljevic, Mohd Moin Khan, Irina Treise, Thure Adler, Juan Antonio Aguilar-Pimentel, Byron Au-Yeung, Eleonora Sittig, Teemu Daniel Laajala, Yiling Chen, Sebastian Oeder, Julia Calzada-Wack, Marion Horsch, Tero Aittokallio, Dirk H Busch, Markus W Ollert, Frauke Neff, Johannes Beckers, Valerie Gailus-Durner, Helmut Fuchs, Martin Hrabě de Angelis, Zhi Chen, Riitta Lahesmaa, Jukka Westermarck   +23 more
doaj   +1 more source

Quantitative analysis of NRF2 pathway reveals key elements of the regulatory circuits underlying antioxidant response and proliferation of ovarian cancer cells [PDF]

, 2014
Cells are constantly exposed to Reactive Oxygen Species (ROS) produced both endogenously to meet physiological requirements and from exogenous sources.
Bown, James, Deeni, Yusuf, Goltsov, Alexey, Harrison, David J., Khalil, Hilal S., Langdon, Simon P.   +5 more
core   +4 more sources

CIP2A influences survival in colon cancer and is critical for maintaining Myc expression. [PDF]

PLoS ONE, 2013
The cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncogenic factor that stabilises the c-Myc protein. CIP2A is overexpressed in several tumours, and expression levels are an independent marker for long-term outcome.
Armin Wiegering, Christina Pfann, Friedrich Wilhelm Uthe, Christoph Otto, Lukas Rycak, Uwe Mäder, Martin Gasser, Anna-Maria Waaga-Gasser, Martin Eilers, Christoph-Thomas Germer   +9 more
doaj   +1 more source

High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia. [PDF]

, 2016
Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a predictive biomarker of disease progression in many malignancies, including imatinib-treated chronic myeloid leukemia (CML).
Butterworth, M., Carmell, N., Clark, R.E., Cohen, G.M., Lucas, C.M., Milani, M., Scott, L.J., Varadarajan, S.   +7 more
core   +1 more source

Cucurbitacin B induces inhibitory effects via the CIP2A/PP2A/C-KIT signaling axis in t(8;21) acute myeloid leukemia

Journal of Pharmacological Sciences, 2019
Acute myeloid leukemia (AML) is the most common subtype of hematological malignancy in humans, and its incidence increases with age. The treatment of AML still faces challenges.
Wenjing Ma, Yuchen Xiang, Rui Yang, Te Zhang, Jiaxin Xu, Yezi Wu, Xuewen Liu, Ke Xiang, Huzi Zhao, Ying Liu, Yuan Si   +10 more
doaj   +1 more source

CIP2A Constrains Th17 Differentiation by Modulating STAT3 Signaling

iScience, 2020
Summary: Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) is an oncogene and a potential cancer therapy target protein. Accordingly, a better understanding of the physiological function of CIP2A, especially in the context of immune cells, is a ...
Mohd Moin Khan, Ubaid Ullah, Meraj H. Khan, Lingjia Kong, Robert Moulder, Tommi Välikangas, Santosh Dilip Bhosale, Elina Komsi, Omid Rasool, Zhi Chen, Laura L. Elo, Jukka Westermarck, Riitta Lahesmaa   +12 more
doaj   +1 more source

Prognostic significance of CIP2A expression in solid tumors: A meta-analysis. [PDF]

PLoS ONE, 2018
CIP2A, cancerous inhibitor of protein phosphatase 2A, was initially recognized as an oncoprotein. Recently several studies revealed that CIP2A could function as a prognosis biomarker, however, the result remained not comprehensive, partly due to small ...
Min Tang, Jiao-Feng Shen, Ping Li, Li-Na Zhou, Ping Zeng, Xi-Xi Cui, Min-Bin Chen, Ye Tian   +7 more
doaj   +1 more source

Recent advances in understanding the relationship between cancerous inhibitor of protein phosphatase 2A and tumors

World Chinese Journal of Digestology, 2009
Anran Qian, Yan Xin, Yu-ping Xiao
semanticscholar   +2 more sources

CIP2A expression predicts recurrences of tamoxifen-treated breast cancer [PDF]

, 2017
CIP2A is emerging as an oncoprotein overexpressed commonly across many tumours and generally correlated with higher tumour grade and therapeutic resistance.
Allred DC, Anderson WF, Baldacchino S, Burstein HJ, Böckelman C, Böckelman C., Cerami E, Chang M-S., Choi YA, Choudhury KR, Cohen DA, Colletta AA, Come C, Coons SJ, Davies C, De P, Gnant M, Guenebeaud C, Hatanaka Y, Junttila MR, Khanna A, Laine A., Landis JR, Liu CY, Liu X, Lucas CM, Manna S, Maraqa L, McGraw KO, McHugh ML., Niemelä M, Petritsch C, Ponten F, Qu W, Ruediger R, Rugo HS, Sengupta S, Shrout PE, Singh G, Stolarova M, Teng H-W, Tseng L-M, Tseng L-M, Vaarala MH, Wang J, Wang J, Wang L, Xu Y, Yu G   +48 more
core   +3 more sources

Colon cancer cell-derived 12(S)-HETE induces the retraction of cancer-associated fibroblast via MLC2, RHO/ROCK and Ca2+ signalling [PDF]

, 2016
Retraction of mesenchymal stromal cells supports the invasion of colorectal cancer cells (CRC) into the adjacent compartment. CRC-secreted 12(S)-HETE enhances the retraction of cancer-associated fibroblasts (CAFs) and therefore, 12(S)-HETE may enforce ...
Bago-Horvath, Zsuzsanna, Brendel, Konstantin Alexander, Brenner, Stefan, De Wever, Olivier, Dolznig, Helmut, Eichsteininger, Julia, Giessrigl, Benedikt, Holzner, Silvio, Huttary, Nicole, Jäger, Walter, Koperek, Oskar, Krenn, Liselotte, Krieger, Sigurd, Krupitza, Georg, Mader, Robert M, Marian, Brigitte, Milovanovic, Daniela, Nguyen, Chi Huu, Schachner, Helga, Schmidt, Wolfgang M, Senfter, Daniel, Stadler, Mira, Stadler, Serena   +22 more
core   +1 more source